Save information for later
Sign Up

Learn About Hepatitis E

View Main Condition: Hepatitis

What is the definition of Hepatitis E?
Hepatitis E is a viral infection of liver that causes inflammation and can damage organs. The disease usually causes acute, short-term infection but can become chronic in people with weakened immune systems, in which case the disease can cause cirrhosis, liver failure, or even death. Hepatitis E is spread by the fecal-oral route, mainly by drinking contaminated water. Other causes are eating undercooked meat from infected animals, such as pork or deer, transfusion with infected blood products, and transmission from a pregnant mother to her baby.
What are the symptoms of Hepatitis E?
Symptoms of hepatitis E usually last for 1-6 weeks and include fever, jaundice (yellowing of whites of eyes and skin), reduced appetite, nausea and vomiting, abdominal pain, rash, itching, joint pain, dark urine and pale stools, and an enlarged, tender liver.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Hepatitis E?
While there is currently no cure for hepatitis E, most people get better without treatment within a few weeks; however, they should remain under the care of a doctor until fully recovered. Treatment for acute hepatitis E includes rest, drinking lots of fluids, and eating healthy foods.  Hospitalization is usually not required, with the exception of pregnant women and infected persons who have developed the severe complication known as fulminant hepatitis. Persons infected with hepatitis E must avoid taking medications that contain acetaminophen/paracetamol and drugs given for nausea and vomiting to prevent further liver damage. Do not drink alcohol until fully recovered. Immunosuppressed persons with chronic hepatitis E may be treated with the antiviral drug, ribavirin, or interferon. While a vaccine has been made for prevention of hepatitis E, it is currently only available in China.
Who are the top Hepatitis E Local Doctors?
Heiner H. Wedemeyer
Elite in Hepatitis E
Elite in Hepatitis E
Carl Neuberg Str. 1, 
Hannover, NI, DE 

Heiner Wedemeyer is a Hepatologist in Hannover, Germany. Mr. Wedemeyer is rated as an Elite expert by MediFind in the treatment of Hepatitis E. His top areas of expertise are Hepatitis D, Hepatitis, Hepatitis C, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Nassim Kamar
Elite in Hepatitis E
Elite in Hepatitis E

CHU Toulouse Rangueil

Toulouse, FR 

Nassim Kamar practices in Toulouse, France. Mr. Kamar is rated as an Elite expert by MediFind in the treatment of Hepatitis E. His top areas of expertise are Hepatitis E, Hepatitis, Cytomegalovirus Infection, Kidney Transplant, and Liver Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Jacques Izopet
Elite in Hepatitis E
Elite in Hepatitis E

CHU Purpan

Toulouse, FR 

Jacques Izopet practices in Toulouse, France. Mr. Izopet is rated as an Elite expert by MediFind in the treatment of Hepatitis E. His top areas of expertise are Hepatitis E, Hepatitis, Hereditary Neuralgic Amyotrophy, Kidney Transplant, and Liver Transplant.

What are the latest Hepatitis E Clinical Trials?
A Phase 2b, Open-label Study to Evaluate the Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adult Participants Followed by a Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Immunogenicity and Safety of Hecolin® in Children

Summary: The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses (0, 1 and 6 months) and to assess and descriptively compare safety profile data intra and inter age Strata. As secondary objectives, Geometric Mean Concentration (GMC) of a...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II, Randomized, Observer-blinded, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women Between Gestational Age 14-34 Weeks and Non-Pregnant Women of 16-45 Years Old.

Summary: This is a phase II randomized, observer-blinded, placebo-controlled study with 3 arms enrolling a total of 2,358 participants. The arms are composed of Arm 1, pregnant participants receiving Hecolin® (N=1,104) with immunogenicity subset (n=150), Arm 2, pregnant participants receiving placebo (N=1,104) with immunogenicity subset (n=150), and Arm 3, non-pregnant participants receiving Hecolin® (N=15...